Fresh2 Group Ltd. Announces Receipt of a Delinquency Compliance Alert Notice from Nasdaq
New York, NY, April 22, 2024 (GLOBE NEWSWIRE) — Fresh2 Group Ltd. (NASDAQ: FRES) (“Fresh2” or the “Company”), a B2B […]
Ekso Bionics to Report First Quarter 2024 Financial Results on April 29, 2024
SAN RAFAEL, Calif., April 22, 2024 (GLOBE NEWSWIRE) — Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader […]
Synchronoss Technologies Announces First Quarter 2024 Earnings Call Date and Participation in Upcoming Investor Events
BRIDGEWATER, N.J., April 22, 2024 (GLOBE NEWSWIRE) — Synchronoss Technologies, Inc. (“Synchronoss” or the “Company”) (Nasdaq: SNCR), a leading global […]
Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024
CORAL GABLES, Fla., April 22, 2024 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company […]
Stereotaxis to Report First Quarter 2024 Financial Results on May 13, 2024
ST. LOUIS, April 22, 2024 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for […]
DTE Energy helps make NFL Draft carbon neutral
Detroit, April 22, 2024 (GLOBE NEWSWIRE) — DTE Energy (NYSE:DTE), Michigan’s largest producer of renewable energy, is working with the […]
Southern States Bancshares, Inc. Announces First Quarter 2024 Financial Results
First Quarter 2024 Performance and Operational Highlights Net income of $8.1 million, or $0.90 per diluted share Core net income(1)of […]
Aterian Announces Improved First Quarter 2024 Net Revenue and Adjusted EBITDA Ranges
First Quarter Net Revenue Range Improved to $20.0 Million to $21.0 Million First Quarter Adjusted EBITDA Loss Range Improved to […]
Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML
– Ziftomenib is the first investigational treatment to be granted Breakthrough Therapy Designation for NPM1-mutant AML – – Registration-directed trial […]
Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
Lexeo Therapeutics gains intellectual property rights including current and future clinical data from ongoing Weill Cornell Medicine investigator-initiated trial of […]
